GKP See insights on Recursion Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Recursion Pharmaceuticals pre-IPO overview from MarketWatch. Unlike traditional biotechnology companies, our rapidly growing team of more than 200 Recursionauts is balanced between life scientists and computational and technical experts, creating an environment where empirical data, statistical rigor and creative thinking is brought to bear on the problems we address. Find the latest Oric Pharmaceuticals, Inc. (ORIC) stock quote, history, news and other vital information to help you with your stock trading and investing. Recursion, a drug discovery startup out of Salt Lake City, Utah has announced a $60 million Series B round, led by Data Collective (DCVC). We operate at the intersection and cutting-edge of science and technology. recursionpharma.com | BioTech | Founded: 2013 | Funding to Date: $333,700,000 Provider of a drug discovery platform designed to interrogate complex biological interactions for drug re-purposing. Recursion Pharmaceuticals is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Recursio n. SALT LAKE CITY--( BUSINESS WIRE)-- Recursion, a digital biology company industrializing drug discovery, today announced it has entered into a global licensing agreement with Takeda Pharmaceutical Company Limited (Takeda) to gain rights to TAK-733, a clinical-stage MEK inhibitor, and develop it for the treatment of a hereditary cancer syndrome and related areas of oncology. 03/25 Trump claims Capitol rioters posed ‘zero threat’ to lawmakers ; 03/25 Fuel tank at Saudi oil facility attacked, catches fire Here's how to buy in when the IPO launches. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. A high-level overview of Recursion Pharmaceuticals (RXRX) stock. Recursion Pharmaceuticals has 206 employees at their 1 location and $437.06 m in total funding,. The CCM program became our first clinical-stage program and remains one of our lead programs today. Recursion started … And so, along with my co-founders Dr. Dean Li (then head of the lab I worked in, now the SVP of Translational Discovery at Merck) and Blake Borgensen (our original CTO and today an ardent advocate for AI ethics), we founded Recursion in 2013. Recursion Pharmaceuticals is expected to go public under the ticker symbol RXRX . Recursion Pharmaceuticals Stock. Intraday Stock Chart Tuesday 6 April 2021 Your Recent History LSE.